Compare Citius Pharmaceuticals Inc (CTXR) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Halliburton Company — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Halliburton Company trades at $32.44 (market cap $26.45B). The key difference: Halliburton Company is far larger — about 1918.1× Citius Pharmaceuticals Inc's market cap, and Halliburton Company pays a 2.14% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Halliburton Company for 89 Days on average.
| CTXR | HAL | |
|---|---|---|
Market Cap | $13.79M | $26.45B |
Volume | 156,684 | 11,229,274 |
Sector | Health | Energy |
52-Week High | $1.82 | $42.98 |
52-Week Low | $0.48 | $21.82 |
Typical Hold Time | 16 Days | 89 Days |
Enterprise Value | $3.96M | $32.60B |
Dividend Yield | — | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Halliburton (HAL) trades at $32.57, down 0.46% on the day, amid a bearish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent news highlights expansion in Venezuela and a major contract win in Cyprus, signaling growth initiatives. Financials show solid profitability with a net income margin of 7.16% and a P/E ratio of 16.62, though 2025 revenue dipped slightly to $22.18 billion.
The outlook is supported by strong analyst consensus with a $43.11 price target and 73% buy ratings, but risks include oil price volatility and execution challenges in new markets. Cash flow trends have been mixed, with 2025 net cash flow negative $412 million, though 2026 projects a return to positive territory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
